1)Shimazaki J, Hanada K, Yagi Y et al:Changes in ocular surface caused by antiglaucomatous eye drops:prospective, randomised study for the comparision of 0.5% timolol v 0.12% unoprostone. Br J Ophthalmol 84:1250-1254, 2000
2)Ishibashi T, Yokoi N, Kinoshita S:Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 12:486-490, 2003
3)Herreras JM, Pastor JC, Calonge M et al:Ocular surface alternation after long-term treatment with an anti-glaucomatous drug. Ophthalmology 99:1082-1088, 1992
4)Baudouin C, de Lunardo C:Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol 82:39-42, 1998
5)Leung EW, Medeiros FA, Weinreb RN:Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 17:350-355, 2008
6)Erb C, Gast U, Schremmer D:German register for glaucoma patients with dry eye. Ⅰ. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol 246:1593-1601, 2008
7)Oh JR, Chang JH, Yoon JS et al:Change in quality of life of patients undergoing silicone stent intubation for nasolacrimal duct stenosis combined with dry eye syndrome. Br J Ophthalmol 99:1519-1522, 2015
8)Soparkar CN, Patrinely JR, Hunts J et al:The perils of permanent punctal plugs. Am J Ophthalmol 123:120-121, 1997
9)McNab, AA:Lacrimal canalicular obstruction associated with topical ocular medication. Aust N Z J Ophthalmol 26:219-223, 1998
10)Labbé A, Terry O, Brasnu E et al:Tear film osmolarity in patients treated for glaucoma or ocular hypertension. Cornea 31:994-999, 2012
11)Tiedemann D, Mouhammad ZA, Utheim TP et al:Conjunctival goblet cells, the overlooked cells in glaucoma treatment. J Glaucoma 28:325-333, 2019